Disease Caused by Rotavirus Infection

Che-Liang Lin 1, §, Shou-Chien Chen 2, 3, §, Shyun-Yeu Liu 4, Kow-Tong Chen*, 5, 6
1 Internal Medicine Chest Division, Chi-Mei Medical Center, Liouying, Tainan, Taiwan
2 Department of Family Medicine, Da-Chien General Hospital, Miaoli, Taiwan
3 General Education Center, Ta Tung University, Taipei, Taiwan
4 Chi-Mei Medical Center, Tainan, Taiwan
5 Department of Occupational Medicine, Tainan Municipal Hospital, Tainan, Taiwan
6 Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan

© Lin et al.; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the Department of Occupational Medicine, Tainan Municipal Hospital, Tainan, Taiwan. No. 670, Chongde Road, East District, Tainan, Taiwan; Tel: +886-6-2609926; Fax: +886-6-2606351; E-mails:,
§ Contributed equally.


Although rotavirus vaccines are available, rotaviruses remain the major cause of childhood diarrheal disease worldwide. The Rotarix (GlaxoSmithKline Biologicals Rixensart, Belgium) and RotaTeq (Merck and Co., Inc. Whitehouse Station, New Jersey, USA) vaccines are effective for reducing the morbidity and mortality of rotavirus infection. This article aims to assess the epidemiology of rotaviral gastroenteritis and the efficacy and effectiveness of licensed rotavirus vaccines. This review concludes by presenting challenges in the field that require further exploration by and perspectives from basic and translational research in the future.

Keywords: Effectiveness, efficacy, rotavirus, rotavirus vaccine..